CD4+ proliferative responses remained largely cross-reactive to Omicron spike, with only 12% (4/33) of individuals with prior infection and/or vaccination and/or booster showing a >50% (0.3log10) reduction (Figure 3B). This evidence concerns the gene CD4 and infection.